2021E3S Web of ConferencesOpen access

Advances in nutritional status of patients with connective tissue-associated pulmonary hypertension

Jiang Jinyan, Li Jin ling, Cheng-jie

Open full text 0 citations

Abstract

Connective Tissue Disease (CTD) is an autoimmune disease involving connective tissues, including sjogren syndrome (pSS), rheumatoid arthritis (RA), systemic sclerosis (SSc), mixed connective tissue disease (MCTD), systemic lupus erythematosus (SLE), etc. [1,2]. Pulmonary Arterial Hypertension (PAH) refers to a pathological condition in which the pulmonary artery pressure rises above a certain threshold, causing right heart failure and death [3]. PAH refers to the mean Pulmonary Artery Pressure (mPAP) of greater than 25 mmHg and the pulmonary wedge pressure (PAWP) of less than 15mmhg under right heart catheterization (RHC) at rest [4,5]. The only criterion for examining pulmonary hypertension is right cardiac catheterization. Connective tissue disease-associated pulmonary hypertension (CTD-PAH) is a rare complication of PAH, characterized by high mortality, venous and cardiac involvement and poor prognosis [6-8].

Open-access reader

About this research paper

What this paper is about

Connective Tissue Disease (CTD) is an autoimmune disease involving connective tissues, including sjogren syndrome (pSS), rheumatoid arthritis (RA), systemic sclerosis (SSc), mixed connective tissue disease (MCTD), systemic lupus erythematosus (SLE), etc. [1,2]. Pulmonary Arterial Hypertension (PAH) refers to a pathological condition in which the pulmonary artery pressure rises above a certain threshold, causing right heart failure and death [3]. PAH refers to the mean Pulmonary Artery Pressure (mPAP) of greater than 25 mmHg and the pulmonary wedge pressure (PAWP) of less than 15mmhg under right heart catheterization (RHC) at rest [4,5]. The only criterion for examining pulmonary hypertension is right cardiac catheterization. Connective tissue disease-associated pulmonary hypertension (CTD-PAH) is a rare complication of PAH, characterized by high mortality, venous and cardiac involvement and poor prognosis [6-8].

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Connective Tissue Disease (CTD) is an autoimmune disease involving connective tissues, including sjogren syndrome (pSS), rheumatoid arthritis (RA), systemic sclerosis (SSc), mixed connective tissue disease (MCTD), systemic lupus erythematosus (SLE), etc. [1,2]. Pulmonary Arterial Hypertension (PAH) refers to a pathological condition in which the pulmonary artery pressure rises above a certain threshold, causing right heart failure and death [3]. PAH refers to the mean Pulmonary Artery Pressure (mPAP) of greater than 25 mmHg and the pulmonary wedge pressure (PAWP) of less than 15mmhg under right heart catheterization (RHC) at rest [4,5]. The only criterion for examining pulmonary hypertension is right cardiac catheterization. Connective tissue disease-associated pulmonary hypertension (CTD-PAH) is a rare complication of PAH, characterized by high mortality, venous and cardiac involvement and poor prognosis [6-8].

Key concepts: Medicine, Mixed connective tissue disease, Pulmonary hypertension, Rheumatoid arthritis, Cardiology, Pulmonary artery, Connective tissue disease, Connective tissue

Related papers

Back to paper searchBrowse research topicsOriginal source
Advances in nutritional status of patients with connective tissue-associated pulmonary hypertension — Research Paper | ScholarLens